Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy скачать в хорошем качестве

Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy

Prof Nielsen talks to ecancertv at SABCS 2015 about data showing that premenopausal women with invasive breast cancers of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy. In a prospectively performed retrospective analysis of the Danish Breast Cancer Cooperative Group (DBCG) 77B study, the aim was determine the predictive value of intrinsic breast cancer subtypes for response to adjuvant chemotherapy. Using tumour specimens from this randomised clinical trial, Prof Nielsen explains how data on the immunohistochemistry of the samples was used to identify the subtype of breast cancer and then assess the effect of adjuvant cyclophosphamide-based chemotherapy. Patients with luminal A breast tumours did not benefit from chemotherapy whereas patients with non-luminal A subtypes did. Prospective trial data are needed to confirm the findings.